ELOX
Eloxx Pharmaceuticals, Inc.
13.90$
+1.1%
vs. previous close
Closing price · As of: Oct 12, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +43.7% | -8.3% | +314.3% | -41.7% | +15.4% | +13.3% | +13.2% | +80.1% | +13.8% | +19.1% | -49.4% | -47.3% | -58.2% | +453.8% | +158.8% | +2.1% | +68.1% | -27.6% | +16.4% | -79.7% | -100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -35.0% | -72.5% | -56.6% | |
| – | -111.9% | – | +24.5% | +18.0% | -443.1% | – | – | – | – | – | -206.7% | – | – | +110.4% | -129.0% | – | – | – | – | -379.1% | – | |
| – | +40.8% | -100.0% | – | +27.6% | +49.9% | -73.4% | +82.5% | +120.0% | -71.2% | +149.0% | +3,736.2% | -100.0% | +4,739,900.0% | -0.8% | -83.0% | -100.0% | – | -25.8% | -100.0% | – | – | |
| – | -64.7% | – | -96.0% | -1,094.3% | +31.5% | – | -384.9% | -34.4% | +17.4% | – | -140.1% | – | – | +178.1% | +10,475.4% | – | -93.9% | -103.2% | – | -87.7% | -97.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -47.4% | |
| – | -24.3% | -99.7% | +20,762.9% | +330.3% | – | – | -86.3% | +94.3% | +24.9% | +116.5% | -44.7% | -76.1% | +3,187.6% | +48.3% | -16.7% | -107.3% | – | -82.6% | -146.3% | – | +219.9% | |
| – | -43.3% | -74.8% | +236.6% | +5,781.3% | -200.5% | – | -157.8% | – | – | +181.4% | -161.6% | – | – | +5.0% | -206.6% | – | +715.5% | -229.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.